Revvity arrives at its August 4 Q2 print with short pressure continuing to ease — but the stock's muted recovery and a divided analyst community mean the debate is far from settled.
The bear retreat has extended since the July 30 earnings date listed in history data. Short interest has now fallen to 6.4% of the free float, down roughly 12% over the past month and off about 2% from a week ago. Borrow conditions remain undemanding: availability runs at 372% — more than three shares available for every one already borrowed — and borrowing costs are negligible at 0.53%. The ORTEX short score has drifted lower too, from a recent peak of 59.2 on July 17 to 53.7, a consistent directional move that reflects the week-by-week reduction in short positioning. Options are similarly relaxed: the put/call ratio of 0.45 is only modestly above its 20-day average and sits nowhere near the defensive spike seen in June. The borrow and derivatives markets are, in short, not pricing in acute stress.
The analyst picture is more contested. The most constructive recent move came from Evercore ISI, which raised its target to $125 in early July while maintaining an Outperform rating — a meaningful step given the stock was trading well below that level at the time. Bernstein reinstated coverage with a neutral Market Perform and a $115 target in late June. That framing captures the central tension: bulls point to the company's shift from TST to IGRA testing as a structural growth driver worth several hundred basis points annually, plus a high-growth software segment and share gains in autoimmune testing. Bears flag the deteriorating China business — revenues from the region expected to fall toward 7% of total and still declining — alongside broader funding headwinds that are cooling lab-spending budgets across life sciences. JP Morgan sits on the cautious side with a $90 Neutral target, well below where the stock now trades at $112.52. The consensus mean of $117 implies modest upside, but the spread between the most bullish and most bearish targets is unusually wide.
Price action offers one more piece of context. After the prior earnings release in May, the stock jumped more than 14% in a single session and held most of that gain over the following week — a reminder that the setup can shift sharply on the day. Peers are broadly in line heading into the session: TMO, CRL and WAT all pulled back modestly on Thursday, while AVTR has surged 20% over the past week, suggesting selective appetite for life-sciences names remains intact even if sector sentiment is uneven.
Tuesday's print is ultimately a test of whether Revvity's underlying diagnostics and software growth is durable enough to justify a stock that has recovered sharply from its April lows — and whether China's drag is stabilising or still widening.
See the live data behind this article on ORTEX.
Open RVTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Revvity posted a clean earnings beat on May 5, and the market responded — the stock jumped 6.7% on the day and ended the week up 8.4% to $92.30. The setup now is a classic post-earnings tension: a short base that was…
Revvity heads into Monday's earnings call with short interest down 4.6% over the past month and borrowing costs soft. Analyst sentiment has cooled sharply since February's post-earnings optimism gave way to April…
